Immunotherapy injected directly into fluid cavities shows promise for pancreatic cancer

NCT ID NCT07230301

Not yet recruiting Disease control Sponsor: Sizhen Wang Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether putting an immunotherapy drug called adebrelimab directly into the chest or belly can help control cancer-related fluid buildup in people with advanced pancreatic cancer. About 20 participants will receive the drug along with standard care. The goal is to see if this approach improves survival and reduces fluid buildup.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Adebrelimab (an immunotherapy drug that helps the immune system fight cancer)
What this could lead to: If it works, this could offer a new way to control painful fluid buildup in the chest or belly for people with advanced pancreatic cancer.
What could go wrong: This is a small, early-phase trial with only 20 people, so results may not apply to everyone. The drug may cause side effects like fatigue or nausea, and it is not yet proven to extend life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER METASTATIC

More trials for these conditions

Other studies related to the condition(s) this trial covers.